[
    [
        {
            "time": "",
            "original_text": "方达控股(01521.HK)拟出售非核心业务新泽医药技术45%的股权 资产异常",
            "features": {
                "keywords": [
                    "方达控股",
                    "新泽医药技术",
                    "股权出售",
                    "非核心业务"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "方达控股(01521.HK)拟出售非核心业务新泽医药技术45%的股权 资产异常",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "生物医药中期业绩爆棚 龙头品种屡创新高",
            "features": {
                "keywords": [
                    "生物医药",
                    "中期业绩",
                    "龙头品种",
                    "创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药中期业绩爆棚 龙头品种屡创新高",
                "Correlation": 5,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "方达控股(01521.HK)附属拟作价720万美元出售Tigermed-BDM 45%的股权",
            "features": {
                "keywords": [
                    "方达控股",
                    "Tigermed-BDM",
                    "股权出售",
                    "720万美元"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "方达控股(01521.HK)附属拟作价720万美元出售Tigermed-BDM 45%的股权",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "以史为鉴，拒绝伪增长！466份中报预告揭秘A股增长点",
            "features": {
                "keywords": [
                    "中报预告",
                    "A股",
                    "增长点",
                    "伪增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "以史为鉴，拒绝伪增长！466份中报预告揭秘A股增长点",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "泰格医药香港子公司拟720万美元购买关联资产 溢价170%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "香港子公司",
                    "关联资产",
                    "溢价170%",
                    "720万美元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药香港子公司拟720万美元购买关联资产 溢价170%",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药全资子公司购买控股孙公司Tigermed-BDM Inc. 45%股权",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Tigermed-BDM",
                    "全资子公司",
                    "股权购买"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药全资子公司购买控股孙公司Tigermed-BDM Inc. 45%股权",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业2019年中期投资策略:医药行业持续变革,创新药械和cro投资机会凸显",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "创新药械",
                    "cro",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2019年中期投资策略:医药行业持续变革,创新药械和cro投资机会凸显",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]